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ABSTRACT 
 
In this work we employ the Fourier Transform Raman Spectroscopy to study normal and 
tumoral human breast tissues, including several subtypes of cancers. We analyzed 194 Raman 
spectra from breast tissues that were separated into 9 groups according to their corresponding 
histopathological diagnosis. The assignment of the relevant Raman bands enabled us to connect the 
several kinds of breast tissues (normal and pathological) to their corresponding biochemical 
moieties alterations and distinguish among 7 groups: normal breast, fibrocystic condition, duct 
carcinoma-in-situ, duct carcinoma-in-situ with necrosis, infiltrating duct carcinoma not otherwise 
specified, colloid infiltrating duct carcinoma and invasive lobular carcinomas. We were able to 
establish the biochemical basis for each spectrum, relating the observed peaks to specific 
biomolecules that play special role in the carcinogenesis process. This work is very useful for the 
premature optical diagnosis of a broad range of breast pathologies. We noticed that we were not 
able to differentiate inflammatory and medullary duct carcinomas from infiltrating duct carcinoma 
not otherwise specified. 
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1. INTRODUCTION 
 
The breast cancer is the most common malignant tumor found in women in the Western 
world. Usually, the breast cancer screening involves two steps. The first one is the search for 
palpable lesions in the annual clinical breast examination. The second one is the X-ray 
mammography, in which suspicious local density changes could be detected. Whenever the tissue 
is particularly dense throughout, ultrasound may also be used to locate suspicious regions. If a 
lesion is found during the examination the tissue is submitted to biopsy that could ranges from the 
fine needle aspiration of single cells to the surgical removal of the entire suspicious mass by 
excisional biopsy. The main problem of the fine needle aspiration procedure is the high rate of false 
positive. Elmore et al.1 have shown that over a 10 years period, during which subjects received a 
median of four mammograms and five clinical breast examinations, 31.7 % of all women 
experienced at least one false positive from either tests. Other inconveniences are related to the time 
expended in waiting the biopsy result as well as the biopsy procedure itself. 
The breast is a large secretory gland composed of 15 to 25 autonomous and empty lobes 
connected to the nipple. The lobes themselves are divided into smaller units, called lobules, which 
are connected by ducts. Lobular and duct elements consist of single layers of epithelial and 
myoepithelial cells.2 The breast undergoes many changes throughout a woman’s life, both 
progressive due to puberty, pregnancy and menopause and cyclical due to menstruation. Hormones 
regulate these changes. This dynamical activity could induce a lot of opportunities for disease. 
Usually, breast pathology is extremely diverse, but it could be divided into two main categories: 
benign and malignant pathologies. Most benign breast lesions are part of a spectrum of fibrocystic 
changes, whereas 70 % of malignant lesions are infiltrating duct carcinomas.2 
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It is well known that the increased cell proliferation and metabolic activity in malignant 
tissues result in changes of the concentration and oxidation states of several biochemical species. 
Singer et al.3 have used 31P- and 13C-nuclear magnetic resonance spectroscopy to compare the 
metabolite levels and fluxes through enzymes regulating phospholipid and mitochondrial 
metabolism of normal mammary epithelial cells with cancer cells. They found a 16-19-fold increase 
in the phosphocholine content in two primary breast cancer cell lines and a 27-fold increase in 
phosphocholine content in the metastatic breast cancer cell line compared with the normal breast 
epithelial cell. They also observed 30 % decrease in the ATP level, 83 % decrease in the 
phosphocreatine levels, 50-80 % relative reduction in the flux of pyruvate utilized for mitochondrial 
energy generation, along with a 2-fold increase in the NAD(+) + NADH levels in 21PT, 21NT, and 
21MT-2 cells in malignant cells compared to the normal cells. This last finding was suggested as 
being an evidence of impaired mitochondrial metabolism in the breast carcinoma cell lines. 
Recently, Brull et al.4 have shown that specific genetic alterations enhance the transport of choline, 
augment the synthesis of phosphocholine and betaine, and suppress the synthesis of choline-derived 
ether lipids in breast cancer cells. Through immunohistochemical and biochemical methods Yeo et 
al.5 had shownthat there are a connection among the increased levels of altered proteoglycans and 
stromal desmoplasia that could explain the alterations in the extracellular matrix synthesis. 
Alterations in the proteoglycans appear in tumors and wound healing tissues where they present 
both, greater heterogeneity and longer glycosaminoglycan chains..  
Similar to other kinds of cancers, the origin of breast cancer is in great extension related to 
multiple genetic alterations and protein dysfunctions.6,7 In particular, the p53 tumor suppressor gene 
mutation remains the most common genetic change identified in the human neoplasia.7 Moreover, 
the common cellular morphological processes evolved in the malignant development as loss of 
differentiation, nuclear enlargement, hyperchromatism, pleomorphism and atypical mitoses could 
induce detectable biochemical changes, e.g., increasing nucleoproteins and nucleic acids.8 Probing 
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these cellular biochemical changes should provide a better understanding of the malignant tumoral 
process mechanism in the human tissues as well as the basis for more precise cancer diagnosis. 
Raman spectroscopy is an optical technique that provides information about the molecular 
vibrational degrees of freedom of the investigated sample being widely used for quantitative and 
qualitative analytical studies in the fields of chemistry, geology, pharmacology, and solid state 
physics. Recently, it has emerged as a nondestructive analytical tool for the biochemical 
characterization of biological systems due to several advantages as sensitivity to small structural 
changes, non-invasive sample capability, and high spatial resolution in the case of Raman 
microscopy. This technique does not require wide sample preparation or pre-treatment, and making 
use of the FT-Raman technique employing light sources in the infrared region, the detection of 
weak Raman signals become easier due to fluorescence suppression. Moreover, the excitation in the 
near infrared, at 1064 nm, also minimizes the photo-degradation of the sample, allowing the 
employment of larger power densities to compensate the weak Raman signal generated by longer 
wavelengths.9 
Alfano et al.10 were the first to employ FT-Raman spectroscopy in the study of human breast 
tissues, using a laser at 1064 nm as excitation source. They studied 14 breast tissues being 3 normal, 
4 benign, and 7 malignant, do not regarding the several subtypes of these carcinomas. They 
observed spectral differences between malignant, benign and normal tissues but they were unable to 
associate these differences to biochemical changes. Redd et al.11 measured the Raman spectra of 
normal breast tissues using visible light at 406.7, 457.9, and 514.5 nm. They found differences 
between the peak intensities of normal and malignant tissues and attributed it to changes in the fatty 
acids and ß-carotene contents. Similar to Alfano et al.10, the work of Redd et al.11 did not concern 
the classification of breast carcinomas subtypes. Frank et al.12 used excitation at 784 nm to obtain 
Raman spectra of normal, benign (fibro-adenoma), and malignant tissues (infiltrating duct 
carcinoma not otherwise specified - NOS). They noticed that the band at 1439 cm-1 in the normal 
tissue shifted to 1450 cm-1 in the infiltrating duct carcinoma NOS and they had attributed this 
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change to the increased protein concentration in malignant samples. Using the ratio among the 1654 
and 1439 cm-1 band areas, they easily differentiate infiltrating duct carcinoma from normal tissue. 
However, they were unable to statistically differentiate among infiltrating duct carcinoma and fibro-
adenoma. 
Manoharan et al.13 proposed the spectral classification of human breast tissues as normal, 
fibro-adenoma or infiltrating duct carcinoma NOS by Raman spectroscopy seeking for the 
identification of predominant spectral components and comparison to their histological diagnosis. 
Using statistical multivariate analysis based on Principal Components Analysis (PCA), Manoharan 
et al.13 were able to correctly classify normal and pathological tissues, while benign and malignant 
spectra remained unclassified on that work. 
Shafer et al.14 have applied confocal micro-Raman spectroscopy to the study of human breast 
tissues. The advantage of the micro over macro-Raman spectroscopy is the relatively small laser 
spot size in the former. While the typical spot in macro-Raman is ~ 50-100 mm it value is ~ 5-
20 mm in the micro case. In this way, Shafer et al.14 were able to make a morphological/chemical 
image of the tissues by fitting the micro-Raman image to a linear combination of basis spectra 
derived from cell cytoplasm, cell nucleous, fatty acids, b-carotene, collagen, calcium 
hydroxiapatite, calcium oxalate dehydrate, cholesterol-like lipids, and water. 
Haka et al.15 studying the chemical composition with micro-Raman spectroscopy of breast 
duct microcalcifications, have shown that microcalcifications of calcium oxalate dihydrate occurs in 
benign lesions while some of those composed of calcium hydroxyapatite could be correlated to 
malignant lesions. 
Yu et al.16 investigating the micro-Raman spectra of normal and malignant breast tissues 
have shown the occurrence of spectral differences involving the bands of symmetric stretching 
modes of -2PO group in the DNA, the symmetric stretching modes of O¾P¾O in RNA, the bands 
of amide I and amide III, and the peak of the C¾O stretching modes in the amino acids. 
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Yan et al.17 analyzing  the Raman spectra of normal and cancerous breast cellshave shown 
that the intensities of the 782 and 1084 cm-1 bands of DNA phosphate group, and 1155 and 
1262 cm-1 of deoxyribose-phosfate had decreased in the cancer cells. Moreover, the bands at 
812 cm-1 of A-type DNA and 979 and 668 cm-1 had disappeared. The authors claim that these 
changes indicate that the phosphate backbone of DNA is partially destroyed in the cancer cells. 
In this work we studied the Raman spectra covering the spectral region of 500 to 2100 cm-1 
of several human breast tissues to obtain a differentiation between normal tissues and 8 subtypes of 
breast pathologies, including fibrocystic condition, duct carcinoma-in-situ, duct carcinoma-in-situ 
with necrosis, infiltrating duct carcinoma-NOS, inflammatory infiltrating duct carcinoma, 
medullary infiltrating duct carcinoma, colloid infiltrating duct carcinoma, and invasive lobular 
carcinoma. Although, differentiation between normal and pathological breast tissues is well 
established in literature, 6, 10, 12, 14, 15, 18-27 the complete differentiation including subtypes of cancer is 
of special interest for clinical applications of Raman spectroscopy and, as far as we are concerned, 
similar study is absent in the literature. 
 
2. METHODOLOGY 
 
This research was done following ethical principles established by the Brazilian Federal Law 
Ministry. The patients were informed about the research and signed permission for collecting their 
tissue samples. 
Pathological breast tissues were obtained from 30 female patients assisted in the Mastology 
Department of the “A. C. Camargo” Hospital, São Paulo, Brazil. Normal breast tissues were 
collected from 5 patients submitted to plastic surgery for breast reduction in private clinics of São 
José dos Campos, Brazil. The samples, soon after the surgical procedure, were identified, snap 
frozen and stored in liquid nitrogen (77 K) in cryogenic vials (Nalgene ®) before the FT-Raman 
spectra recording. For FT-Raman data collection, samples were brought to room temperature and 
 8
kept moistened in 0.9 % physiological solution to preserve their structural characteristics, and 
placed in a windowless aluminum holder for the Raman spectra collection. Soon after, the samples 
were fixed in 10 % formaldehyde solution, to further histopathological analysis. We noticed that the 
chemical species presented in the physiological solution (Ca2+, Na+, K+, Cl-, water) did not have 
measurable Raman signal and their presence did not affect the spectral signal of the tissues. 
A FT-Raman spectrometer (Bruker RFS 100/S) was used with an Nd:YAG laser at 1064 nm 
as excitation light source. The laser power at the sample was kept at 110 mW while the 
spectrometer resolution was set to 4 cm-1. The spectra of normal and pathological breast tissues 
were recorded with 100 and 150 scans, respectively. 
Based on the results of the histopathological diagnosis, the spectra obtained in this study 
were divided in nine groups: (1) normal breast; (2) fibrocystic condition; (3) duct carcinoma-in-situ; 
(4) duct carcinoma-in-situ with necrosis; (5) infiltrating duct carcinoma NOS; (6) inflammatory 
infiltrating duct carcinoma; (7) medullary infiltrating duct carcinoma; (8) colloid infiltrating duct 
carcinoma and (9) invasive lobular carcinoma. After subtracting the baseline, each spectrum was 
normalized to the maximum intensity peak (@1446 cm-1). Afterwards, we obtained the average 
spectrum of each group. Typically, the average was performed over 20 spectra. We estimate the 
dispersion between the spectra within each group to be< 15 %. For the succeeding analysis we 
consider those spectra presenting a correlation coefficient better than 70 % within each group. 
 
3. RESULTS AND DISCUSSION 
In Fig. 1 we show the average Raman spectrum for each of the above-cited groups 
normalized to the 1446 cm-1 peak. This band corresponds to C¾H deformation mode of methylene 
group and it is nearly conformational insensitive. For this reason, it is a good standard for biological 
Raman spectral normalization. The spectra were vertically translated for clarity. All groups 
presented almost the same set of bands and the characteristic features that could differentiate normal 
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from pathological tissues correspond to relative intensity increase/decrease of some bands or 
absence/appearance of some weak peaks. Several authors had pointed out this fact. 6, 10, 12, 14, 15, 18-27 
In the Table 1 we show the frequencies of the 12 main vibrational modes observed in the 
average Raman spectra of all groups. These frequencies were obtained after deconvoluting each 
spectrum into a sum of Lorentzian peaks. Comparing these data with the literature one could assign 
each band to a specific molecular vibration.27-29 These assignments are presented in the Table 2 and 
enable one to perform a qualitative biochemical analysis of the normal and pathological breast 
tissues by confronting spectroscopic and histopathological data. 
In Fig. 2 we show the average non-normalized Raman spectra between 1200 and 1800 cm-1. 
The spectra were vertically translated for clarity and the intensity of the normal tissue was 
multiplied by 1/5. At first glance, the pathological tissues are immediately identified by the strong 
decrease in the intensity of their main bands when compared to the normal tissue. Referring to the 
Table 2, one could infer that the strong Raman bands at 1270, 1304, 1446, 1657, and 1747 cm-1 can 
identify the large amount of lipids present in the normal breast tissue. These modes are related to 
the bond stretching of C¾N, C=C, and C=O and bond twisting of CH2, respectively. Redd et al.11 
identified differences in the lipids and carotene concentrations in breast tissues by Raman 
spectroscopy. They have shown that these bands are strongest in the normal breast than in the fibro-
adenoma and carcinoma duct ones. They proposed that these spectral characteristics could promote 
differential diagnosis among normal tissue and benign or malignant pathologies. 
Histopathologically the normal tissues analyzed in our study have shown, as main 
pathological features, alterations in the collagen content when compared to duct carcinoma-in-situ 
and infiltrating, while the others tissues presented necrosis, inflammatory cells, cysts, and DNA 
content variation. 
In Fig. 3 and 4 we have grouped the results for normal tissue, duct carcinoma-in-situ and 
duct carcinoma infiltrating that present as main histopathological characteristic alterations in the 
collagen content. In Fig. 3 we show the average normalized Raman spectra between 800 and 
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1400 cm-1. The four selected areas in Fig. 3 indicate the bands of amino acids proline, valine, 
glycine, and phenylalanine that characterize the primary structure of proteins. The breast 
pathological tissues are mainly composed of collagen 2 and proline, valine, glycine, and 
phenylalanine are the main collagen’s amino acids.30 It is clear the intensity increase of these bands 
in the tumoral tissue compared to the normal one, especially when the carcinoma becomes 
infiltrating. The origin of this intensity variation probably relies on the different collagen amounts 
present in normal and pathological tissues.2 Moreover, it is known that the relative abundance of 
collagen increases in the carcinogenic process of skin,19 lung,31 breast,14 and epithelial cancers in 
general.27 For breast cancers in particular, due to desmoplastic reaction, also called reactive fibrosis, 
occurs deposition of abundant collagen as a stromal response to an invasive carcinoma. Structures 
relatively remote from the cancer itself may be involved such as Coopers ligaments and duct 
structures between the tumor and the nipple.2 Thus, it is expected that the Raman spectra of 
infiltrating ductal carcinoma show more intense proline, valine, glycine, and phenylalanine 
collagen’s bands than other tissues. This fact was just observed in fibro-adenoma, 27 infiltrating 
ductal,14, 27 and invasive lobular carcinomas.27 Considering that the infiltrating ductal carcinoma 
NOS is the most pathogenic of the breast cancers, the relative collagen content, as determined by 
Raman spectroscopy, could be used as breast cancer pathogenicity quantifier. 
In Fig. 4 we show the average normalized Raman spectra between 1200 and 1800 cm-1. The 
selected areas indicate the amide I and amide III bands corresponding to vibrational modes of the 
peptide bonds of the secondary structure of proteins. These peaks also became more intense in the 
malignant tissues, especially in the infiltrating carcinoma. The amide I band corresponds to 
vibration of C, O, and H atoms in the   –CONH– group.28 The amide III band involves the motion of 
C–radical, C–N, and N–H groups.28 Mahadevan-Jansen et al.29 also observed these bands by 
studying the role of the proteins in the benign and malignant breast tissues. Beyond the spectral 
differences between benign and malignant tissues our results show that there are measurable 
differences in the secondary structure of proteins of breast tissues that could differentiate subtypes 
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of malignant lesions, as ductal carcinoma-in-situ and infiltrating ductal carcinoma, and jointly with 
collagen content could be used to quantify the degree of pathogenicity of breast cancer. 
In Fig. 5 we compare the duct carcinoma-in-situ with and without necrosis analyzing the 
spectral differences of the necrotic elements. In this figure we show the average normalized Raman 
spectra of the duct carcinoma-in-situ with and without necrosis in the spectral range of 800 to 
1800 cm-1. In the stippled area we indicate the low intensity bands that shown a relative intensity 
increase in the tissue with necrosis. As shown in the Table 2, the peaks in the region of 1304-1310, 
~ 1446, and 1657-1660 cm-1 are vibrational modes of adenine, cytosine, collagen, lipids, 
carbohydrates, proteins, and pentoses, respectively. These bands are very similar to those seen by 
Shafer et al.14 in the cholesterol sample simulating necrosis. The intensity differences could be 
related to the presence of necrosis and lymphocytes in the tissue with necrosis. The lymphocytes 
appear due to the inflammatory process in this tissue sample. Thus, this spectral region could be 
useful to diagnose the presence of necrosis in breast cancer tissues. 
In Fig. 6 we compare fibrocystic condition to infiltrating ductal carcinoma NOS and colloid 
infiltrating ductal carcinoma in order to analyze the cystic spectral features. In this figure we show 
the average normalized Raman spectra of the fibrocystic, infiltrating duct and colloid carcinoma 
tissues in the spectral range of 800 to 1200 cm-1. The selected areas indicate the main bands that 
suffer alterations. The intensity variation of the bands in the interval of 800 to 1000 cm-1 is related 
to different collagen contend, as just commented in Fig. 3. Carbohydrate bands that are related to 
the amorphous substance of the cystic content dominate the region between 1020 and 1140 cm-1. 
The vibrational bands at 1065 and 1085 cm-1 are related to the ¾CH¾OH bond and C¾O 
stretching coupled to the C¾O group of the carbohydrates. The bands at 1050, 1065 and 1150 cm-1 
of infiltrating duct carcinoma, fibrocystic and colloid infiltrating duct carcinoma present an 
increasing intensity. This fact could be used to classify these three subtypes of carcinomas, and it 
refers to the different colloid content present in the samples. 
 12
In Fig. 7 and 8 we compare the normal tissue, carcinoma ductal-in-situ, infiltrating ductal 
carcinoma and invasive lobular carcinoma relating the invasiveness potential to the cysteine content 
and CºC band. Fig. 7 shows the average normalized Raman spectra in the region of 500 to 580 cm-
1. We found that there are special features in this region that could be of interest for the clinical 
diagnosis between normal, “in situ” and infiltrating tissues. The most intense peak, at 538 cm-1, is 
related to disulphide bridges in cysteine and it presents a strong intensity increase when compared 
to the normal tissue. The invasive tumors showed more intense peaks than carcinoma-in-situ. 
Thomssen et al.32 have shown that the lysosomal cysteine proteases cathepsin B and cathepsin L 
have been implicated in tumor spread and metastasis, underlining the significance of tumor-
associated proteolysis for invasion and metastasis. In this way the observed intensity variation of 
the Raman band at 538 cm-1 in normal tissue, “in situ” and infiltrating carcinomas could be well 
understood when keeping in mind these changes in cysteine content occurring in tumoral process. 
For this reason, this spectral region could be used to perform initial diagnosis and real-time 
differentiation between “in situ” and infiltrating lesions. Unfortunately from our data we were not 
able to differentiate infiltrating ductal from infiltrating lobular carcinomas. 
Fig. 8 shows the average normalized Raman spectra in the region between 2000 and 
2100 cm-1 for the same set of tissues of Fig. 7. One could observe that the peaks at 2028 and 
2084 cm-1 for ductal carcinoma-in-situ present a 5-fold intensity increase compared to normal 
tissue. For infiltrate ductal and invasive lobular carcinomas this intensity increase is nearly 10 
times. Thus, the spectral differences in these two bands could be used to distinguish among tissues 
with these malignancies and normal tissues. These two peaks are related to CºC bonds 28 that could 
be present in unsaturated fatty acids, lipids and steroids. Unfortunately, we could not identify 
specific biomolecules responsible for this vibration in breast tissues. The low intensity peak at 
2062 cm-1 for ductal carcinoma-in-situ, invasive lobular carcinoma and normal tissue is near to the 
noise level and we will not analyze it. We noticed that we are not able to differentiate inflammatory 
and medullary duct carcinomas from infiltrating duct carcinoma NOS. 
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4. CONCLUSION 
 
In summary, in this study we analyzed the Raman spectra of normal and tumoral breast 
tissues, including several subtypes of cancers, searching for specific spectral features that could 
differentiate normal and pathological tissues. The collected samples were histopathologically 
classified into 9 groups according to their morphological features. Through the qualitative analysis 
of the Raman spectra and assignment of the relevant bands from the literature, it was possible to 
built spectral models and differentiates among 7 groups normal breast, fibrocystic condition, duct 
carcinoma-in-situ, duct carcinoma-in-situ with necrosis, infiltrating duct carcinoma NOS, colloid 
infiltrating duct carcinoma and invasive lobular carcinoma. These differences were established 
through the comparative study between the spectral differences and the histopathological diagnosis. 
Furthermore, we were able to establish the biochemical basis for each spectrum by relating the 
observed peaks to specific biomolecules that have special role in the carcinogenesis process. We 
noticed that we were not able to differentiate inflammatory and medullary duct carcinomas from 
infiltrating duct carcinoma NOS. Our results were summarized in Fig. 9. This work is very useful 
for the precocious optical diagnosis of a broad range of breast pathologies and as far as we are 
concerned, similar work had not been made in the literature. 
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Tables 
 
Table 1- Vibrational mode frequencies (cm-1) observed by Raman spectroscopy in the human breast 
tissues groups (1) normal; (2) fibrocystic; (3) duct carcinoma-in-situ; (4) duct carcinoma-in-situ 
with necrosis; (5) infiltrating duct carcinoma NOS; (6) inflammatory infiltrating duct carcinoma; (7) 
medullary infiltrating duct carcinoma; (8) colloid infiltrating duct carcinoma, and (9) invasive 
lobular carcinoma. 
 
Peaks (1) (2) (3) (4) (5) (6) (7) (8) (9) 
1 - 538.9 538.95 541.35 538.92 538.68 538.72 538.76 538.64 
2 858.75 861.7 858.4 860.75 854.08 853.34 854.57 869.38 853.51 
3 - 935.6 - 942.87 964.83 970.27 962.09 976.14 971.26 
4 1005 1005.3 - 1005.1 1005.4 1004.7 1004.8 1007.1 1005.7 
5 1080.6 1091.4 1080.7 1076.2 1082.4 1084.4 1095.6 1091.6 1083.5 
6 1266.6 1261.2 1264.1 1264.2 1262.5 1261.1 1274.5 1277.2 1266.9 
7 1304 1305.4 1304.8 1310.6 1305.2 1303.8 1303.3 1305.4 1303.6 
8 1446.4 1449.4 1447.5 1450.6 1448.6 1448 1450.2 1449.6 1447.8 
9 1657.1 1657.7 1657.8 1643.0 1659.5 1659.1 1659.7 1657.1 1657.8 
10 1747.4 1747.6 1746.4 - 1748.1 1746.4 1743.5 1748 1747.8 
11 - - 2028.9 - 2028.9 2029 2029.3 2028.5 2029 
12 - - 2084.2 - 2084.2 2083.7 2083.6 2079.1 2084.3 
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Table 2 - Assignment of the main regions observed by Raman spectroscopy in normal and 
pathological human breast tissues. d and n correspond to stretching and twisting vibrational 
modes of the corresponding chemical bond.27-29 
Peaks position (cm-1) Vibrational Mode Major Assignments 
~ 538 S¾S disulphide bridges in cysteine 
853-869 n(C¾C), ring breathing, n(O¾P¾O) proline, tyrosine, DNA 
935-975 n(C¾C), a-helix 
proline, valine, protein 
conformation, glycogen 
~ 1005 symmetric ring breathing mode phenylalaline 
1080-1095 
n(C¾C) or n(C¾O), n(C¾C) or 
n(PO2), n(C¾N), n(O¾P¾O) 
lipids, nucleic acids, proteins, 
carbohydrates 
1260-1275 n(C¾N) of amide III, n(=C¾H) proteins (a-helix), lipids 
1304-1310 d(CH2), d(CH3CH2) adenine, cytosine, collagen, lipids 
~ 1446 d(CH2) 
lipids, carbohydrates, proteins and 
pentose 
1657-1660 n(C=O) of amide I, n(C=C) proteins (a-helix), lipids 
~ 1746 n(C=O) lipids 
~ 2028, 2062, 2084 n(CºC) lipids, fatty acids or hormones 
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Figure Captions 
 
Figure 1 – Normalized average Raman spectrum of  (1) normal; (2) fibrocystic condition; (3) duct 
carcinoma-in-situ; (4) duct carcinoma-in-situ with necrosis; (5) infiltrating duct carcinoma; (6) 
infiltrating duct carcinoma inflammatory; (7) infiltrating duct carcinoma medullar; (8) infiltrating 
duct carcinoma colloid and (9) infiltrating lobular carcinoma groups. The spectra were vertically 
translated for clarity. 
Figure 2 – Non-normalized average Raman spectrum of (1) normal; (2) fibrocystic condition; (3) 
duct carcinoma-in-situ; (4) duct carcinoma-in-situ with necrosis; (5) infiltrating duct carcinoma 
NOS; (6) inflammatory infiltrating duct carcinoma; (7) medullary infiltrating duct carcinoma; (8) 
colloid infiltrating duct carcinoma, and (9) invasive lobular carcinoma in the spectral region of 1200 
to 1800 cm-1. The spectra were vertically translated for clarity and the intensity of normal tissue (1) 
was multiplied by 1/5. 
Figure 3 - Normalized average Raman spectra between 800 and 1400 cm-1 for normal tissue and in-
situ/infiltrating duct carcinomas. 
Figure 4 - Normalized average Raman spectra between 1200 and 1800 cm-1 for normal tissue and 
in-situ/infiltrating duct carcinomas. The selected areas indicate the amide I and amide III bands 
corresponding to the peptidic bonds in the secondary structure of proteins. 
Figure 5. Normalized average Raman spectra of the “in situ” duct with and without necrosis tissues 
in the spectral range of 800 to 1800 cm-1. In the stippled area are indicated the low intensity bands 
that are very similar to those seen by Shafer et al.14 in the cholesterol sample simulating necrosis. 
Figure 6. Normalized average Raman spectra of the fibrocystic condition, infiltrating duct 
carcinoma NOS and colloid type in the spectral range of 800 to 1200 cm-1. 
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Figure 7. Normalized average Raman spectra in the region of 500 to 580 cm-1. The most intense 
peak at 538 cm-1 represent the amino acid cysteine. 
Figure 8. Normalized average Raman spectra in the region between 2000 and 2100 cm-1. The peaks 
at 2028 and 2083 cm-1 are related to proteins and nucleic acids. 
Figure 9. Summary of the several breast cancers classes studied in this work and their 
corresponding main Raman spectral differences. At left we present the main biomolecular vibration 
enabling one to discriminate the specific kind of tissue indicated in the right. 
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